An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis
NCT ID: NCT01561521
Last Updated: 2013-07-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
90 participants
INTERVENTIONAL
2012-03-31
2012-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
NCT01881113
A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
NCT01685242
A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis
NCT03379311
Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis
NCT00241319
Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model
NCT01134328
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AKF-1 0.025%
AKF-1
1 drop AKF-1 0.025% in each eye at 2 separate times during a 14 day period
AKF-1 0.035%
AKF-1
1 drop AKF-1 0.035% in each eye at 2 separate times during a 14 day period
AKF-1 0%
AKF-1
1 drop 0% in each eye at 2 separate times during a 14 day period
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AKF-1
1 drop AKF-1 0.025% in each eye at 2 separate times during a 14 day period
AKF-1
1 drop AKF-1 0.035% in each eye at 2 separate times during a 14 day period
AKF-1
1 drop 0% in each eye at 2 separate times during a 14 day period
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* any ocular condition that, in the opinion of the investigator, could affect the subjects safety or trial parameters
* use of disallowed medication during the period indicated prior to the enrollment or during the study
10 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Akorn, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Andover Eye Associates
Andover, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
11-100-0008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.